Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Till, Brian G  [Clear All Filters]
2024
Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, R Black G, Woodward KBlake, Vartanian N, Kanaan SB, Yeh AC, et al. HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Blood. 2024.
2023
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, Coffey DG, Tuazon SA, Wood B, Gooley T, et al. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811-822.
2021
Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol. 2021;8(8):e562-e571.
2018
Till BG. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Curr Treat Options Oncol. 2018;19(9):45.
2015
Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, et al. Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission. Biol Blood Marrow Transplant. 2015.